Therapeutic Peptides intermediate
Triptorelin Sustained Release
Long-acting triptorelin depot formulations for sustained GnRH receptor suppression in prostate cancer and central precocious puberty.
By Encyclopeptide Editorial | 1 min read
triptorelin sustained-release depot GnRH prostate-cancer
Chemical Identity
| Property | Value |
|---|---|
| Chemical Formula | C64H82N18O14 |
| Molecular Weight | 1311.46 g/mol |
| CAS Number | 57773-63-4 |
| Product Names | Trelstar, Decapeptyl |
Formulation
Triptorelin is available in microsphere depot formulations providing 1-month, 3-month, and 6-month sustained release. PLGA microspheres encapsulate the peptide for controlled subcutaneous release.
Clinical Applications
- Advanced prostate cancer
- Central precocious puberty (children >=2 years)
- Endometriosis (off-label)
- Assisted reproduction (triggering oocyte maturation)
Biological Significance
This molecule plays important roles in biological systems and has potential therapeutic applications.
References
- Encyclopeptide Database. “Triptorelin Sustained Release” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about Triptorelin Sustained Release with interactive quizzes on Wikipept.
Take a Quiz on Wikipept